In a patient with systemic lupus erythematosus and secondary postural orthostatic tachycardia syndrome, is congenital adrenal hyperplasia more likely than 5‑α‑reductase deficiency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Congenital Adrenal Hyperplasia is More Likely Than 5-α-Reductase Deficiency in SLE with Secondary POTS

In a patient with systemic lupus erythematosus (SLE) and secondary postural orthostatic tachycardia syndrome (POTS), congenital adrenal hyperplasia (CAH)—specifically non-classical CAH (NCCAH)—is substantially more likely than 5-α-reductase deficiency. The clinical association between NCCAH and POTS has been documented, whereas 5-α-reductase deficiency has no established relationship with either SLE or POTS 1.

Epidemiologic and Clinical Reasoning

Prevalence Considerations

  • NCCAH affects 0.1–3.7% of the general population depending on ethnicity, making it one of the most common autosomal recessive disorders 2.
  • 5-α-reductase deficiency is exceedingly rare and typically presents with disorders of sex development, ambiguous genitalia at birth, or virilization at puberty in 46,XY individuals 3.
  • The baseline probability of NCCAH is orders of magnitude higher than 5-α-reductase deficiency in any unselected patient 2.

Direct Clinical Association with POTS

  • A documented case report describes a patient with NCCAH who developed POTS, with improvement following calcitriol supplementation for concurrent 1-α-hydroxylation deficiency 1.
  • No published literature links 5-α-reductase deficiency to POTS or SLE 3.
  • POTS predominantly affects young women (approximately 80% of cases), and NCCAH similarly presents more commonly in females with hyperandrogenic symptoms 4, 2.

Adrenal Involvement in SLE

  • Adrenal insufficiency occurs in SLE patients, with case reports documenting acute adrenal crisis as a presenting feature of SLE 5, 6.
  • NCCAH involves impaired cortisol biosynthesis and compensatory adrenal androgen excess, which could theoretically be unmasked or exacerbated by autoimmune adrenal involvement in SLE 2.
  • The adrenal gland is a recognized target in autoimmune diseases, and SLE can cause adrenal hemorrhage, infarction, or autoimmune adrenalitis 5.

Diagnostic Approach for NCCAH in This Clinical Context

When to Suspect NCCAH

  • Hyperandrogenic features: hirsutism (60–80%), acne (30%), androgenic alopecia (2–8%), menstrual irregularities (56%) 7, 2.
  • Premature pubarche or tall stature in childhood (if historical data available) 7.
  • Infertility or recurrent miscarriage in women of reproductive age 8.
  • Symptoms resistant to standard dermatologic or gynecologic treatment 7.

Diagnostic Testing Algorithm

  1. Measure early-morning baseline serum 17-hydroxyprogesterone (17-OHP) during the follicular phase in menstruating women 9.

    • >300 nmol/L suggests classic CAH; 6–300 nmol/L suggests NCCAH; <6 nmol/L is normal 9.

  2. If baseline 17-OHP is 6–300 nmol/L, perform cosyntropin (ACTH) stimulation test 9.

    • Administer 250 mcg cosyntropin IV or IM and measure 17-OHP at 60 minutes 9.
    • Post-stimulation 17-OHP >300 nmol/L confirms classic CAH; 31–300 nmol/L confirms NCCAH; <50 nmol/L suggests unaffected or carrier status 9.

  3. Use liquid chromatography-tandem mass spectrometry (LC-MS/MS) rather than immunoassay to avoid false positives from cross-reactivity 9.

  4. Obtain a complete adrenocortical profile after stimulation (including 21-deoxycortisol, androstenedione, testosterone, deoxycorticosterone, 11-deoxycortisol) to differentiate 21-hydroxylase deficiency from 11β-hydroxylase deficiency or P450 oxidoreductase deficiency 9.

  5. Reserve genetic testing (CYP21A2 sequencing) for equivocal hormonal results or when genetic counseling is needed 9.

Common Pitfalls to Avoid

  • Do not measure 17-OHP during the luteal phase or during pregnancy, as physiologic elevations will confound interpretation 9.
  • Do not rely on immunoassay alone, as cross-reactivity with other steroids produces false positives 9.
  • Do not assume heterozygous carriers are unaffected; they may show modest post-ACTH 17-OHP elevations that overlap with normal subjects 9.
  • Do not target complete normalization of 17-OHP during treatment, as this leads to supraphysiologic glucocorticoid dosing and iatrogenic Cushing's syndrome 8.

Why 5-α-Reductase Deficiency is Unlikely

Clinical Presentation Mismatch

  • 5-α-reductase deficiency presents with disorders of sex development in 46,XY individuals, including ambiguous genitalia at birth, micropenis, hypospadias, or virilization at puberty 3.
  • It does not cause hyperandrogenism in 46,XX individuals (who would be unaffected carriers) 3.
  • There is no documented association with SLE or POTS in the medical literature 3.

Diagnostic Considerations

  • If 5-α-reductase deficiency were suspected (which it should not be in this context), diagnosis would require:
    • Elevated testosterone-to-dihydrotestosterone (T/DHT) ratio after hCG stimulation.
    • Genetic testing for SRD5A2 mutations.
    • Karyotype analysis to confirm 46,XY genotype 3.

Treatment Implications if NCCAH is Confirmed

Indications for Glucocorticoid Therapy

  • Initiate glucocorticoid treatment for clinically important hyperandrogenism (marked hirsutism, acne, androgenic alopecia) 8.
  • Treat infertility or recurrent miscarriage with glucocorticoids 8.
  • Address menstrual irregularities causing significant symptoms 8.

Preferred Regimen

  • Dexamethasone 0.25 mg once daily effectively reduces acne and irregular menstruation within approximately 3 months and improves hirsutism over 30 months 8.
  • Alternative agents include cyproterone acetate, spironolactone, or estrogen-progestin combinations for women who wish to avoid glucocorticoid exposure 2.

Monitoring to Avoid Overtreatment

  • Watch for iatrogenic Cushing's syndrome (weight gain, hypertension, impaired glucose tolerance) 8.
  • Assess hyperandrogenic symptoms (hirsutism, acne, alopecia) regularly rather than targeting complete hormonal normalization 8.
  • NCCAH patients do not require stress-dose glucocorticoids, as there is no clinically significant cortisol deficiency or risk of adrenal crisis 8.

POTS Management Considerations

  • If 1-α-hydroxylation deficiency is identified (low 1,25-dihydroxyvitamin D despite normal 25-hydroxyvitamin D), consider calcitriol 0.25 mcg daily, as this has been associated with POTS remission in a patient with NCCAH 1.
  • Standard POTS management (volume expansion, salt supplementation, compression garments, fludrocortisone, midodrine, beta-blockers) should be implemented concurrently 10.

References

7
Guideline

american association of clinical endocrinologists medical guidelines for the clinical practice for the diagnosis and treatment of hyperandrogenic disorders.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2001

8
Guideline

Guideline Recommendations for Symptomatic Non‑Classical Congenital Adrenal Hyperplasia (NCCAH)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

9
Guideline

Diagnostic Evaluation of Elevated 17‑Hydroxyprogesterone for Congenital Adrenal Hyperplasia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

How should I adjust glucocorticoid and mineralocorticoid therapy in a 39-year-old Caucasian female with congenital adrenal hyperplasia who presents with hyponatremia and elevated total testosterone while taking prednisone 2.5 mg three times daily, spironolactone 100 mg twice daily, and fludrocortisone 0.1 mg twice daily?
In a 15-year-old girl with postural orthostatic tachycardia syndrome (POTS) who is taking mirtazapine for decreased appetite and insomnia, how should the medication be managed regarding dosing, monitoring, and possible alternatives?
In a 26-year-old female with a history of fibromyalgia and postural orthostatic tachycardia syndrome (POTS) presenting with new-onset spinal pain, what is the appropriate workup?
In a patient with suspected postural orthostatic tachycardia syndrome (POTS) and hypermobility who is taking lisdexamfetamine (LDX) 70 mg daily and venlafaxine extended‑release (XR) ≥150 mg daily, is it appropriate to add a low‑dose (5–10 mg) immediate‑release dexamphetamine in the early morning to improve alertness before LDX takes effect, and how should it be titrated and monitored?
In a 14-year-old male with postural orthostatic tachycardia syndrome presenting with exertional tachycardia and vomiting, what cardiac and other evaluations and management steps should be considered?
Can drotaverine be given to a patient with acute appendicitis who is awaiting surgery?
What are the typical estimated fetal weights for each gestational age (weeks) in a normal singleton pregnancy?
How long does it typically take for most blood pressure medications to begin lowering blood pressure?
Do all statins cause thrombocytopenia (low platelet count)?
I am on my first day of nebivolol (Bystolic) 15 mg and now have tachycardia (HR ≈ 103 bpm), hypertension (BP ≈ 145/101 mm Hg), chest burning and headache after stopping metoprolol—should I go to the emergency department or how should I manage this?
What is the recommended management of hepatitis C infection during pregnancy, including testing, treatment timing, delivery method, and breastfeeding guidance?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.